Multi-Center Phase II Clinical Trial on Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinoma after Failure of Treatment with 1st-Line TKI Therapy.
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 23 Jun 2017 Status changed from active, no longer recruiting to completed.
- 01 Feb 2014 Results presented at the 2014 Genitourinary Cancers Symposium.
- 17 Jan 2013 Planned end date added (11 Jan 2015) as reported by University Hospital Medical Information Network - Japan.